Citations

Clear

128 citation(s) found for "Nathan, Foster".

Association of tumor infiltrating lymphocytes (TILs) with molecular subtype and prognosis in stage III colon cancers (CC) from a FOLFOX-based adjuvant chemotherapy trial.
Smyrk, Thomas C. , Foster, Nathan R. , Meyers, Jeffrey P., Thibodeau, Stephen N. , Goldberg, Richard M. , Sinicrope, Frank A. , Shi, Qian , Sargent, Daniel J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3518-3518

10.1200/jco.2016.34.15_suppl.3518 Get It

MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer.
Long, Beverly, Hou, Xiaonan , Becker, Marc A., VanBlaricom, Jamison L., Bradley, Evans, Hendrickson, Andrea E. Wahner , Oberg, Ann L. , Heinzen, Ethan P. , Camoriano, John , Colón‐Otero, Gerardo , Burton, Jill K., Kalli, Kimberly R., Foster, Nathan R. , Weroha, Saravut J., Maurer, Matthew J. , Haluska, Paul

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS5609-TPS5609

10.1200/jco.2016.34.15_suppl.tps5609 Get It

Mutation analysis in metastatic colorectal cancers (mCRC) subjected to gene panel testing for BRAF and KRAS genes in clinical practice.
Foster, Nathan R. , Kipp, Benjamin R. , Voss, Jesse S. , Jones, Jeremy C , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e15049-e15049

10.1200/jco.2016.34.15_suppl.e15049 Get It

Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant trial: NCCTG N0147 (Alliance).
Lee, Hee Eun , Foster, Nathan R. , Smyrk, Thomas C. , Sinicrope, Frank A. , Shi, Qian , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3583-3583

10.1200/jco.2018.36.15_suppl.3583 Get It

A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101.
Foster, Nathan R. , Zoroufy, Alexander J., Souza, Jonas A. de, Jelinek, Michael J. , Schwartz, Gary K. , Münster, Pamela N. , Seiwert, Tanguy Y. , Vokes, Everett E.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 6031-6031

10.1200/jco.2018.36.15_suppl.6031 Get It

Phase I trial of TAS-102 and concurrent radiation therapy for patients with locally recurrent, unresectable or metastatic, rectal cancer.
Hallemeier, Christopher L. , Ahn, Daniel H. , Mishra, Nitin , Foster, Nathan R. , Grothey, Axel, Hubbard, Joleen M. , Leal, Alexis D. , Hallemeier, Christopher Leigh , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS3623-TPS3623

10.1200/jco.2018.36.15_suppl.tps3623 Get It

Abstract LB-305: Randomized, double-blind, placebo-controlled immunoprevention trial with MUC1 vaccine in patients with newly diagnosed advanced adenomas
Boardman, Lisa A., Bansal, Ajay , Beatty, Pamela , Hur, Chin , Dzubinski, Lynda , Rodriguez, Luz M. , Salazar, Andres , McKolanis, John , Seisler, Drew K., Foster, Nathan R. , Polley, May-Yin, Finn, Olivera J. , Schoen, Robert E. , Boardman, Lisa A., Cruz‐Correa, Marcia , Kastenberg, David , RODRIGUEZ, LUZ MARIA , Limburg, Paul J.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: LB-305-LB-305

10.1158/1538-7445.am2018-lb-305 Get It

Abstract Background: Immunotherapy targeting tumor-associated antigens aberrantly expressed on colorectal cancers and adenomatous polyps offers the potential for a relatively non-invasive and non-toxic prevention strategy, and because of the specificity of the immune response and its long-term memory, the potential for prolonged protection. In a double-blind randomized trial in patients with a diagnosis of advanced colorectal adenomas within the previous year, we are evaluating MUC1 vaccine with the TLR-3 agonist polyICLC (Hiltonol®) as an adjuvant, for its immunogenicity and effect on colorectal adenoma recurrence at follow up colonoscopy. Aim: We report on a primary endpoint, MUC1 immunogenicity at week 12 (following vaccine or placebo administration at 0, 2, and 10 weeks), and on determinants of the immune response and vaccine toxicity. Methods: Subjects with an advanced adenoma (defined as ≥1cm, tubulovillous or villous histology, or with HGD) were randomized. Response to the vaccine was assessed by monitoring IgG anti-MUC1 antibody titer ratio; defined as t12/t0, where t0 is the initial titer measured prior to vaccination, and t12 is the titer drawn at 12 weeks. A ratio of 2.0 was used as the primary definition of a significant immune response. T Regulatory and myleoid derived suppressor cell (MDSC) levels at baseline were assessed in relation to vaccine response. Adverse events (AEs) were recorded according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Results: 102 subjects were randomized at 6 centers, 52 received MUC1 vaccine and 50 placebo. Subjects had a mean age of 59.4±7.0 (range 40-70) years, 60.8% were male, 88.2% were white, and 18.6% Hispanic or Latino. At 12 weeks the IgG ratio was ≥2.0 in 13/52 (25%) of patients receiving vaccine (ratio range 2.9-17.3), vs. 0/50 in placebo group (P=.0001), and was ≥1.5 in 19/52 (36.5%) of patients receiving vaccine compared to 1/50 (2%) in placebo group (P<.0001). In the vaccinated group, the IgG ratio was ≥2.0 in 45% of women (9/20) vs. 12.5% of men (4/32) (P=0.009) and ≥1.5 in 55% of women (11/20) vs. 25% of men (8/32) (P=0.03). In the vaccinated group, reduced levels of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) pre-vaccination were associated with response, 0.2±0.1 among responders (n=13) vs. 0.8±1.1 among non-responders (N=39) (p=0.0006) whereas monocytic MDSC and T regulatory cells (CD4+CD25, Foxp3) were not. There were no grade 3 adverse events (AE) possibly or probably related to the vaccine. The most common AE was an injection site reaction (grade 1 or 2) which occurred in 80.8% (n=42/52) in vaccine group vs. 6.0% in the placebo group (3/50). Conclusions: Subjects with an advanced adenoma receiving MUC1 vaccine compared with a placebo are significantly more likely to develop an anti-IgG MUC1 immune response at 12 weeks. Women and subjects with lower circulating PMN-MDSC levels at baseline were more likely to respond. The vaccine was well tolerated. Follow up for the effect of the vaccine on adenomatous polyp recurrence is ongoing. Citation Format: Robert E. Schoen, Lisa A. Boardman, Marcia Cruz-Correa, Ajay Bansal, Pamela L. Beatty, David Kastenberg, Chin Hur, Lynda Dzubinski, Luz Rodriguez, Andres Salazar, John McKolanis, Drew Seisler, Nathan R. Foster, May-Yin Polley, Paul J. Limburg, Olivera J. Finn. Randomized, double-blind, placebo-controlled immunoprevention trial with MUC1 vaccine in patients with newly diagnosed advanced adenomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-305.
Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E
Katipamula, Rajini, Jatoi, Aminah , Foster, Nathan R. , Nichols, Francis, Rubin, Joseph, Callister, Matthew D., Gunderson, Leonard L., Nichols, Francis C., Alberts, Steven R.

Mayo Clinic

Clinical medicine. Oncology | September 14, 2017 | Volume: 2 | Issue: No issue available | Pages: No page available

10.4137/cmo.s444 | PMID 21892283 Get It

Purpose This brief report describes a planned, interim, 6-patient toxicity analysis that confirms the safety of pemetrexed, carboplatin, radiation with subsequent surgery, as prescribed in the North Central Cancer Treatment Group trial N044E, in patients with locally advanced esophageal cancer. Methods Six patients with locally advanced, potentially resectable esophageal cancer received pemetrexed 500 mg/m 2 and carboplatin AUC = 6 on days 1 and 22 with 5040 centigray of concomitant radiation in 28 fractions over 5.5 weeks followed by esophagectomy as a prelude to a phase II multi-institutional trial. Results Only 1 of the 6 patients experienced a grade 4 adverse event (neutropenia). This patient also experienced a grade 3 depression. Of the remaining 5 patients, three experienced at least one grade 3 adverse event (neutropenia, nausea/vomiting, and esophagitis). There were no deaths. Incidentally, one patient manifested a complete pathologic response, three a partial pathologic response, and one stable disease. Conclusion These preliminary observations on safety suggest that this regimen can be further studied in this clinical setting.
Should Vital Signs be Routinely Obtained Prior to Intravenous Chemotherapy? Results from a 2-Center Study
Menon, Smitha, Foster, Nathan R. , Looker, Sherry, Sorgatz, Kristine, Jatoi, Aminah , Kasi, Pashtoon Murtaza , McWilliams, Robert R.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 22 | Issue: 4 | Pages: 515-519

10.1177/107327481502200419 | PMID 26678980 Get It

A Single-Institution Study of Demographics and Outcomes of Adult Patients with Multiple Cancers
Ho, Thanh P. , Foster, Nathan R. , Jatoi, Aminah

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 23 | Issue: 4 | Pages: 455-460

10.1177/107327481602300418 | PMID 27842336 Get It

Background Few studies have described the demographics and outcomes in patients with multiple cancers. Methods We reviewed the health records of patients with at least 3 invasive solid-tumor malignancies (lung, colorectal, pancreatic, prostate, breast, or ovarian) diagnosed between 1995 and 2014 at our institution. Results A total of 163 patients were identified. The median age at first cancer diagnosis was 61 years. Sixteen (10%) had a family history of cancer, and 7 (4%) had a cancer-predisposing syndrome. Most had early-stage malignancies and underwent a series of surgical resections. The median survival from the first cancer diagnosis was 14 years (95% confidence interval: 12–16). Forty-three percent developed 4 or more cancers. In univariate analyses, older age, male sex, smoking history, concurrent cancer, and stage IV disease were associated with worse survival; by contrast, breast cancer as the first cancer diagnosis yielded better survival. In multivariate analyses, older age, smoking history, and stage IV disease were associated with worse survival. Conclusions A small group of patients with no ostensible risk factors develop multiple early-stage cancers, receive curative therapy (often surgery), and live for years. These patients merit further study to ascertain the broader prevalence rates of individuals with multiple invasive cancers and to better understand factors that contribute to cancer risk.